Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBX7 | O95931 | 1/20 | 0.35 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | PYGL | P06737 | 2/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496913 | 0.89 | SNRNP200 (0.39) | CBX7CDYLKMT2ASNRNP200F11 | |
| SCHEMBL2514984 | 0.87 | SNRNP200 (0.35) | CBX7CDYLKMT2ASNRNP200IDO1 | |
| SCHEMBL2492782 | 0.87 | PYGL (0.44) | CBX7CDYLKMT2AF11PYGL | |
| SCHEMBL2492829 | 0.85 | KMT2A (0.40) | CBX7CDYLKMT2ASNRNP200IDO1 | |
| SCHEMBL2496408 | 0.85 | CBX7 (0.40) | CBX7CDYLKMT2ASNRNP200IDO1 | |
| SCHEMBL2497643 | 0.85 | PYGL (0.39) | CBX7CDYLKMT2ASNRNP200IDO1 | |
| SCHEMBL2498534 | 0.84 | CBX7 (0.39) | CBX7CDYLKMT2ASNRNP200IDO1 | |
| SCHEMBL2501794 | 0.84 | CBX7 (0.39) | CBX7CDYLKMT2ASNRNP200IDO1 | |
| SCHEMBL2494983 | 0.83 | NPC1 (0.39) | CBX7CDYLF11PYGL | |
| SCHEMBL2500596 | 0.83 | MMP9 (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | CBX7 4226/4885CDYL 3793/4885KMT2A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.